-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Maintains Overweight on Avalyn Pharma, Lowers Price Target to $53

Benzinga·11/16/2026 15:00:10
Listen to the news
Morgan Stanley analyst Judah Frommer maintains Avalyn Pharma (NASDAQ:AVLN) with a Overweight and lowers the price target from $57 to $53.